CS-8958 - A Phase I, Double-blind, Placebo-controlled, Ascending, Multiple Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Subjects.
Latest Information Update: 02 Nov 2011
At a glance
- Drugs Laninamivir (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions
- Sponsors Biota Holdings
Most Recent Events
- 02 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 02 Dec 2009 Actual end date (Nov 2009) added as reported by ClinicalTrials.gov.
- 23 Oct 2009 New trial record